Enanta Pharmaceuticals Inc (ENTA)

[tika1]

ALVR also has an RSV program.

ALVR106 is an allogeneic, off-the-shelf, multi-virus specific T-cell therapy candidate designed to target human metapneumovirus (hMPV), influenza, parainfluenza virus (PIV), and respiratory syncytial virus (RSV).

Recent setbacks in T-cell therapy, such as Atara Biosecience's failure in MS, raise questions about the field's overall effectiveness. This could potentially remove a competitor from the RSV space, making ALVR106 more attractive to larger pharmaceutical companies.